Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
US-2015352154-A1 · Dec 10, 2015 · US
Treating myelin diseases with optimized cell preparations
US9709553B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9709553-B2 |
| Application number | US-99087409-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 7, 2009 |
| Priority date | May 8, 2008 |
| Publication date | Jul 18, 2017 |
| Grant date | Jul 18, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The disclosure relates to oligodendrocyte-biased glial progenitor cells and methods of making, isolating, and using such cells.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of isolating a population of human oligodendrocyte-biased glial progenitor cells, comprising the steps of: (a) providing a population of human neural cells or neural precursor cells and (b) recovering a population of A2B5+ and PSA-NCAM− human oligodendrocyte-biased glial progenitor cells from the provided population of human neural cells or neural precursor cells using only an agent that selectively binds to the CD140a ectodomain epitope of human PDGFαR, wherein the recovered population of cells has a higher percentage of said human oligodendrocyte-biased glial progenitor cells than when said recovering is carried out using antibodies directed against A2B5 and PSA-NCAM. 2. The method of claim 1 , wherein the recovering step is performed by FACS or magnetic sorting. 3. The method of claim 1 , wherein the agent is an antibody. 4. The method of claim 1 , wherein the recovered human oligodendrocyte-biased glial progenitor cells are immortalized. 5. The method of claim 4 , wherein the recovered human oligodendrocyte-biased glial progenitor cells express an exogenous nucleic acid encoding a human telomeric extension reverse transcriptase. 6. The method of claim 1 , wherein the provided population is derived from human neural tissue. 7. The method of claim 1 , wherein the provided population is derived from human multipotent or pluripotent stem cells. 8. The method of claim 7 , wherein the human pluripotent stem cells are induced human pluripotent stem cells. 9. The method of claim 1 , wherein the provided population is derived from human fetal cells. 10. The method of claim 1 , wherein the provided population is derived from human non-fetal cells. 11. The method of claim 1 further comprising: culturing the recovered human oligodendrocyte-biased glial progenitor cells under conditions effective to form human oligodendrocytes. 12. The method of claim 1 , further comprising: culturing the recovered human oligodendrocyte-biased glial progenitor cells under conditions effective to form human astrocytes.
Assignees
Inventors
Classifications
Ophthalmic agents · CPC title
Drugs for disorders of the nervous system · CPC title
Stem cells · CPC title
- C12N5/0622Primary
Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells · CPC title
- G01N33/5058Primary
Neurological cells · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9709553B2 cover?
- The disclosure relates to oligodendrocyte-biased glial progenitor cells and methods of making, isolating, and using such cells.
- Who is the assignee on this patent?
- Goldman Steven, Sim Fraser J, Univ Rochester
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0622. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).